What is the appropriate workup for microscopic hematuria in an 84-year-old patient?

Microhematuria Workup in an 84-Year-Old Patient

An 84-year-old patient with microscopic hematuria requires risk stratification using the 2025 AUA/SUFU guidelines, followed by comprehensive urologic evaluation including upper tract imaging and cystoscopy if classified as intermediate or high-risk, which is highly likely given their age alone. 1

Risk Stratification

At age 84, this patient automatically meets high-risk criteria for men (≥60 years) or intermediate-risk criteria for women (≥60 years) based on age alone 1. The 2025 guidelines notably revised the classification system so that women cannot be categorized as high-risk based solely on age, reflecting data showing significantly lower risk of urothelial malignancy in women 1.

Additional factors that determine final risk category include:

• Degree of hematuria: 3-10 RBC/HPF (low), 11-25 RBC/HPF (intermediate), >25 RBC/HPF (high)
• Smoking history: <10 pack-years (low), 10-30 pack-years (intermediate), >30 pack-years (high)
• History of gross hematuria (automatically high-risk if previously unevaluated)
• Additional urothelial cancer risk factors: occupational/environmental exposures, family history, prior pelvic radiation 1

Initial Evaluation

Perform a focused assessment targeting:

• Detailed smoking history with pack-year quantification (strongest modifiable risk factor for bladder and kidney cancer)
• Blood pressure measurement and serum creatinine to assess for medical renal disease
• History of gross hematuria, irritative voiding symptoms, family history of urologic malignancies
• Occupational/environmental exposures to carcinogens
• Physical examination including assessment for gynecologic causes in women 1

Diagnostic Workup Based on Risk Category

For High-Risk Patients (Men ≥60 years with additional risk factors)

Upper tract imaging is mandatory:

• CT urography is the preferred modality for comprehensive evaluation of the urothelium
• Alternative: MR urography if CT contraindicated
• Renal ultrasound alone is insufficient for high-risk patients 2

Cystoscopy should be performed to evaluate the lower urinary tract for bladder masses, urethral stricture disease, and benign prostatic hyperplasia 2

Urine cytology is NOT recommended in the initial evaluation, as it has not demonstrated incrementally additive information to cystoscopy and lacks sufficient predictive value 2

For Intermediate-Risk Patients (Women ≥60 years)

The same comprehensive evaluation applies:

• Upper tract imaging (CT urography preferred)
• Cystoscopy
• No routine urine cytology 1, 2

Special Considerations at Age 84

Important caveat: At 84 years old, shared decision-making becomes critical. The 2025 guidelines emphasize balancing cancer detection against the risks of over-evaluation, particularly given that aggressive workup carries risks of unnecessary procedures, radiation exposure, and anxiety 1. However, recent data shows women over 70 have a 2.2% incidence of bladder cancer, suggesting they warrant thorough evaluation 3.

Consider the patient's:

• Overall health status and life expectancy
• Functional status and ability to tolerate procedures
• Competing comorbidities that may affect cancer-specific vs. all-cause mortality
• Patient preferences regarding invasive testing

When to Suspect Renal (Glomerular) Disease

If the following are present, concurrent nephrology referral is warranted:

• Dysmorphic red blood cells or cellular casts
• Proteinuria
• Elevated creatinine
• Hypertension 2, 4

These findings suggest glomerular hematuria requiring nephrologic rather than urologic evaluation.

Special Scenarios

Family history of renal cell carcinoma or genetic renal tumor syndromes (von Hippel-Lindau, Birt-Hogg-Dube, hereditary papillary RCC, hereditary leiomyomatosis RCC, tuberous sclerosis): Perform upper tract imaging regardless of risk category 2

Follow-Up After Negative Evaluation

If initial workup is negative but hematuria persists:

• Engage in shared decision-making regarding additional evaluation 2
• Consider urine cytology only if patient has irritative voiding symptoms or other risk factors for carcinoma in situ 2
• Repeat evaluation is warranted if patient develops gross hematuria, significant increase in degree of microscopic hematuria, or new urologic symptoms 2

Common Pitfalls to Avoid

1. Do not use urine dipstick alone - microscopic hematuria must be confirmed with microscopy showing ≥3 RBC/HPF 1
2. Do not skip evaluation in elderly patients - age is a primary risk factor, and malignancy risk increases with age 1, 3
3. Do not order routine urine cytology - it adds no value to initial evaluation and increases costs without improving detection 2
4. Do not use renal ultrasound alone for high-risk patients - it misses urothelial lesions and is inadequate for comprehensive evaluation 2
5. Do not dismiss persistent hematuria after UTI treatment - if hematuria persists after appropriate antibiotic therapy, proceed with full urologic evaluation 4

The 2025 AUA/SUFU guidelines represent the most current evidence-based approach, with validation studies confirming their effectiveness for stratifying urothelial cancer risk 3. However, these guidelines are less predictive for renal cortical neoplasms, emphasizing the importance of comprehensive imaging regardless 3.